Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

doi:10.1016/S1470-2045(22)00555-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

The Lancet. Oncology - 1 Nov 2022

Bidard François-Clément, Hardy-Bessard Anne-Claire, Dalenc Florence, Bachelot Thomas, Pierga Jean-Yves, de la Motte Rouge Thibault, Sabatier Renaud, Dubot Coraline, Frenel Jean-Sébastien, Ferrero Jean Marc, Ladoire Sylvain, Levy Christelle, Mouret-Reynier Marie-Ange, Lortholary Alain, Grenier Julien, Chakiba Camille, Stefani Laetitia, Plaza Jérôme Edouard, Clatot Florian, Teixeira Luis, D'Hondt Véronique, Vegas Hélène, Derbel Olfa, Garnier-Tixidre Claire, Canon Jean-Luc, Pistilli Barbara, André Fabrice, Arnould Laurent, Pradines Anne, Bièche Ivan, Callens Céline, Lemonnier Jérôme, Berger Frédérique, Delaloge Suzette

Abstract excerpt

BACKGROUND: In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show the efficacy of an early change in therapy on the basis of a rising ESR1 mutation in blood (bESR1mut), while assessing the global safety of combination fulvestrant and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Aromatase Inhibitors

Share to Disease-Free Survival

Share to Fulvestrant

Share to Lymphopenia

Share to Neutropenia

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Source

Open in PubMed

Identifiers

PMID: 36183733
DOI: 10.1016/S1470-2045(22)00555-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.PMID 36183733Read ↗

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.Semantic proximity Read ↗

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.Semantic proximity Read ↗

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.Semantic proximity Read ↗

Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.Semantic proximity Read ↗

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.Semantic proximity Read ↗

304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trialSemantic proximity Read ↗

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatmentSemantic proximity Read ↗

ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.Semantic proximity Read ↗

Switching ahead of progression: Insights from the SERENA-6 trial on targeting emerging ESR1 mutations in advanced HR+/HER2- breast cancer.Semantic proximity Read ↗

Clinical significance on Switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancerSemantic proximity Read ↗

PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of E Health-Based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated with Palbociclib and an Aromatase Inhibitor- or Palbociclib and FulvestrantSemantic proximity Read ↗

Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.